Thanks Mike, I was only asking for your predictions - I don't expect anyone to be able to be able to answer questions that don't yet have an answer.
You seem to have connections that the rest of us don't, so your predictions would be of much greater interest that those of a random small investor, to wit:
Based on the success of the first Phase III, based on people already using B12 for allergies and athletes getting B12 shots for energy, and based on the well established safety profile of B12, I think both trials have a very good chance of being successful.
So my prediction on the trials: both are successful and statistically significant, clearly sufficient for submission to the FDA.
I would think it in Cobalis' best interests to sign a partner as soon as possible after good results so they can launch Prehistin as soon as the FDA approves it. But unless a lot of groundwork has already been laid, I'd expect negotiations and due diligence by all companies involved to take a while.
So my prediction number 2: No quick partnership after positive trial results.
Since I personally bought some shares at $1.80 a while back, I think CLSC will prove to be significantly undervalued if good trial results are announced. This is somewhat offset by virtually no one knowing about CLSC, so I'll give CLSC a few days after good trial results for the general public to find them and buy in.
My prediction number 3: CLSC price one week after positive trial results announced: $4.50, and this is the low side of the range I could see CLSC possibly climbing to.
I won't bother guessing at the price if the trials don't reach statistical significance, suffice to say it will be extremely ugly.
AI
